Latest California Healthline Stories
Cheaper Over-The-Counter Hearing Aids Could Be On The Way
The FDA and other agencies are loosening restrictions on hearing aid sales and opening the door to less expensive, over-the-counter products.
Medicare Failed To Recover Up To $125 Million In Overpayments, Records Show
Medicare overpaid five insurance plans by $128 million yet only recovered $3 million, audits show.
GOP’s Timetable For Getting Repeal To Trump May Be Ambitious
Republicans say they plan to pass a bill to overhaul the federal health law in the 17 days between when Congress convenes and Inauguration Day. But past congressional budget veterans say that could prove to be very difficult.
Grab Bag Of Goodies In 21st Century Cures Act
A breakdown of winners — and a few losers — in the sprawling Cures Act approved by the House.
Senate Approves Landmark Mental Health Bill As Part Of 21st Century Cures Act
The U.S. Senate passed a landmark bill to help millions of Americans suffering from mental illness.
Health Law’s Test Kitchen For Payment Reforms Could Offer Tool For GOP Ideas
The Centers for Medicare & Medicaid Innovation was charged by the health law with exploring payment reforms that could cut health care costs and possibly improve quality. But its future is hinged to whether GOP lawmakers see value in its work.
Legislation To Improve Mental Health Care For Millions Faces Congressional Vote
Sponsors of Congressional action up for vote Wednesday have championed mental health changes since the 2012 Newtown shootings.
A Frenzy Of Lobbying On 21st Century Cures
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
Price’s Appointment Boosts GOP Plans To Overhaul Medicare And Medicaid
Privatizing the Medicare program for the elderly and disabled and turning the Medicaid program for the poor back to the states are long-time goals for Republicans in Congress and the White House.
Long-Stalled FDA Reform Sits On Senate’s Lame-Duck Calendar
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.